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ABSTRACT
Background: We describe a severe form of congenital
myasthenic syndrome (CMS) associated with congenital
nephrosis and ocular malformations caused by two
truncating mutations in the gene encoding the laminin b2
subunit (LAMB2).
Methods and results: Mutational analysis in the
affected patient, who has a history of a serious untoward
reaction to treatment with acetylcholinesterase inhibition,
revealed two frame-shifting heteroallelic mutations, a
maternally inherited 1478delG and a paternally inherited
4804delC. An anconeus muscle biopsy demonstrated a
profound distortion of the architecture and function of the
neuromuscular junction, which was strikingly similar to
that seen in mice lacking laminin b2 subunit. The findings
included: pronounced reduction of the axon terminal size
with encasement of the nerve endings by Schwann cells,
severe widening of the primary synaptic cleft and invasion
of the synaptic space by the processes of Schwann cells,
and moderate simplification of postsynaptic folds and
intact expression of the endplate acetylcholinesterase.
The endplate potential quantal content was notably
reduced, while the frequencies and amplitudes of
miniature endplate potentials were only moderately
diminished and the decay phases of miniature endplate
potentials were normal. Western blot analysis of muscle
and kidney tissue and immunohistochemistry of kidney
tissue showed no laminin b2 expression.
Conclusion: This case, which represents a new type of
synaptic CMS, exemplifies the wide variability of
phenotypes associated with LAMB2 mutations and
underscores the fundamental role that laminin b2 plays in
the development of the human neuromuscular junction.
Congenital myasthenic syndromes (CMS) repre-
sent a diverse group of neuromuscular disorders
characterised by varying degrees of muscle weak-
ness and fatigability resulting from impaired
neuromuscular transmission. These syndromes
are classified into presynaptic, synaptic basal-
lamina-associated, and postsynaptic subgroups
depending on which compartment of the neuro-
muscular junction (NMJ) is primarily targeted by
the disease.1 2 To date, mutations in 11 human
genes have been implicated in the pathogenesis of
CMS. Mutations causing postsynaptic CMS have
been identified in genes encoding both the fetal
and the four adult subunits of the acetylcholine
receptor (CHRNG (MIM 100730), CHRNA1
(100690), CHRNB1 (100710), CHRND (100720),
and CHRNE (100725)), rapsyn (RAPSN (601592)),
MuSK (MUSK (601296)), Dok-7 (DOK7 (610285)),
and the skeletal muscle sodium channel (SCN4A
(603967)).1–7 In addition, defects in genes encoding
choline acetyltransferase (CHAT (118490)), and the
collagenic tail subunit of the acetylcholinesterase
(COLQ (603033)) have been found to associate
with presynaptic CMS and synaptic basal-lamina-
associated CMS, respectively.8 9
Mutations in the gene encoding the laminin b2
subunit (LAMB2 (150325)) have been found to be
responsible for Pierson syndrome (MIM 609049),
which is characterised by congenital nephrosis and
ocular defects.10 The majority of the reported
LAMB2 defects are truncation mutations, which
result in a complete lack of laminin b2 immuno-
reactivity in the glomerular basal membrane as
well as a severe phenotype that leads to death
within days or months after birth.10
Laminins are multidomain heterotrimeric glyco-
proteins of the basal lamina composed of one a,
one b, and one c chains.11 In mammals, there are
currently five a, four b and three c isoforms
described, which assemble into no fewer than 15
different heterotrimers.12 The different laminin
isoforms are expressed in a tissue and develop-
mental stage specific manner.13 The laminin
trimers that are expressed at the NMJ are primarily
laminin-4, -9 and -11, which all contain the b2
chain encoded by LAMB2.14 The essential role that
laminin b2 plays in the organisation of the NMJ is
demonstrated by the observation that mice lacking
laminin b2 (Lamb22/2) show defective neuromus-
cular synapses and die within the first weeks of
life.15 In these laminin b22/2 mutants, Schwann
cell processes, which normally cap the NMJ with-
out entering into the synaptic space, intrude into
the primary cleft and impair neuromuscular
transmission.15
PATIENT AND FINDINGS
Our patient, who is currently a 20-year-old
woman, was born to non-consanguineous parents.
During the neonatal period she experienced several
episodes of respiratory distress, and she was found
to have persistently constricted pupils and massive
proteinuria. A renal biopsy at that time demon-
strated findings consistent with a microcystic
nephrosis. All of her motor developmental mile-
stones were delayed, and although her nephrotic
syndrome was corrected at the age of 15 months
after a successful kidney transplant from her
father, her motor deficit persisted. At the age of
7 years a muscle biopsy revealed non-specific
changes, but an electromyogram with repetitive
stimulation at 3 Hz of the left median nerve
resulted in a 24% decrement of the compound
muscle action potential amplitude, which became
more pronounced with higher frequencies of
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stimulation. Serum antibodies against the acetylcholine recep-
tor (AChR) were negative, and a brain magnetic resonance
image (MRI) was normal. A trial with a cholinesterase inhibitor
resulted in profound weakness requiring hospitalisation and
ventilatory support; however, she responded well to treatment
with ephedrine. When she was 9 years old she required
corrective surgery for severe ptosis. At that time an ophthalmo-
logic examination revealed pronounced miosis, myopia and
impaired visual acuity in both eyes. Fundoscopic examination
revealed hypoplastic macular areas and poor foveal reflex, but
her electroretinogram was normal. A neurologic examination
revealed normal cognition, impaired visual acuity and reactive
pinpoint pupils. Her external ocular movements were limited to
15–20u in the horizontal axis, and she had bilateral ptosis. She
showed no bulbar deficit, but the motor examination revealed
severe proximal limb weakness. She had spine surgery for
scoliosis at the age of 12, and since then she has used bi-level
positive airway pressure during night sleep and intermittently
during the day.
To elucidate the nature of the CMS in this patient, we
performed an anconeus muscle biopsy at age 10, which included
in vitro microelectrode recordings as previously described.16 The
most remarkable finding of the microelectrode recordings was
the profound reduction of the quantal content of end plate
potentials (EPPs) evoked by nerve stimulation at 1 Hz relative
to the controls (table 1, t =25.88, p,0.001). Nerve stimulation
at higher frequencies resulted in an even more severe reduction
of the EPP quantal content as shown by the estimate of the
ratio of EPP quantal content using 20 Hz stimulation to 1 Hz
stimulation, which was decreased relative to controls.
Frequencies and amplitudes of miniature endplate potentials
(MEPPs) were also diminished (t = 3.55, p,0.05). However, the
half-decay phases of MEPPs were not different from recordings
performed in age matched controls (table 1). At two endplates
MEPPs were recorded under voltage clamp conditions. The
decay time constants of the resultant miniature endplate
currents (MEPCs) were not different from controls (mean
(SEM) 3.71 (0.15) ms, n = 2 in the patient; and 3.58 (0.16) ms,
n = 11 in controls). Finally, to verify that the endplate
acetylcholinesterase was active we measured the amplitudes
and half-decay phases of the MEPPs recorded before and after
exposure of the preparation to 0.1 mM neostigmine. The average
amplitude and half-decay phase of MEPPs recorded before
neostigmine exposure, 1.16 (0.67) mV and 2.94 (0.67) ms,
respectively, increased to 1.42 (0.62) mV and 6.08 (0.88) ms
after exposure of the muscle to neostigmine, thus indicating
that the endplate acetylcholinesterase was active.
Except for occasional small angular fibres and type I fibre
predominance there were no other histological abnormalities.
The acetylcholinesterase reaction performed in teased muscle
fibre bundles revealed, as in control muscles, only one endplate
per muscle fibre; however, the mean endplate area of 169.9
(16.6) mm2 (17) in the patient was reduced in comparison with
the mean endplate area of 227.03 (11.9) mm2 (40) in controls.
The most consistent structural abnormality of the NMJ
shown by electron microscopy were: (1) small axon terminal
size and encasement of nerve endings by the Schwann cell; (2)
severe widening of the primary synaptic clefts with invasion of
the synaptic space by processes of Schwann cells; and (3)
moderate simplification of the postsynaptic membranes (fig 1).
The small nerve terminals, which often appeared divided into
multiple very small segments and retracted from the post-
synaptic membrane, were in all cases partially or completely
encased by processes of the Schwann cells. As a result of the
encasement of the nerve terminal and invasion of the synaptic
space by the Schwann cell, the areas of apposition between the
nerve terminal and the postsynaptic membrane were extremely
small, and even in these areas where presynaptic membranes
were directly apposed to postsynaptic membranes the primary
synaptic cleft was notably widened. Occasional active zones
were seen in the nerve terminal, but they were not consistently
apposed to the secondary clefts, as seen in the controls. Some
nerve terminals showed a relatively normal number of synaptic
vesicles, while others showed few synaptic vesicles. Overall,
there was a mild reduction in the density of synaptic vesicles
compared to the controls. In the postsynaptic region, there was
simplification of the postsynaptic membranes, which was
variable and minor compared to the extreme hypoplasia of the
axon terminals. There was no other postsynaptic abnormality,
with the exception of two sub-sarcolemmal nuclei containing
degenerating membranous debris.
The morphometric analysis of the NMJ was performed as
previously described16 and revealed that relative to the controls,
our patient showed diminished average axon terminal area and
number of synaptic vesicles per area (table 2). The width of the
primary synaptic cleft was notably increased and the area of
direct apposition of the nerve terminal to the postsynaptic
membranes was extremely small (fig 1). There was also a
reduction of the endplate index (ratio of postsynaptic mem-
brane length/presynaptic membrane length), although the
average number of secondary folds per mm of primary cleft
was not decreased.
After obtaining a signed consent approved by the institu-
tional review board of the University of California Davis, we
amplified and sequenced genomic DNA from all 32 exons of the
human LAMB2 gene and encountered two novel LAMB2
mutations (fig 2, supplemental table 1). Both mutations are
single base pair deletions, resulting in frameshifts. 1478delG
occurs in exon 11, while 4804delC occurs in exon 29. 1478delG
results in an early stop codon at amino acid 496, and 4804delC
creates a termination codon at amino acid 1653. Mutational
analysis in the patient’s family revealed that the 1478delG
mutation derives from the patient’s unaffected mother. In
contrast, the 4804delC mutation is derived from the patient’s
unaffected father and is also carried by the patient’s unaffected
brother. Mutational analysis in CHRNA1, CHRNB, CHRND,
CHRNE, RAPSN, MUSK, DOK7 and COLQ was performed as
previously described16 and showed no abnormalities.
Because both genetic defects encountered in LAMB2 are
deletions leading to frame shifts, we predicted that the protein
would be truncated and fail to assemble with the rest of the
subunits. Indeed, both Western blot, performed as previously
described,17 in kidney and muscle tissues, and immunohisto-
chemistry in kidney tissue showed no expression of laminin b2
(fig 3, supplemental fig 1).
Table 1 Physiological data
Patient Control
MEPPs amplitude (mV) 1.04 (0.12)* (n = 10) 1.58 (0.13) (n = 18)
MEPP decay (ms) 3.81 (0.33) (n = 10) 3.14 (0.19) (n = 18)
MEPP frequency (MEPPS/min) 1.59 (0.30)* (n = 9) 5.55 (1.07) (n = 11)
EPP quantal content (1 Hz) 2.21 (0.43)** (n = 5) 12.61 (1.20) (n = 18)
EPP quantal content (20 Hz/1 Hz) 0.65 (0.067)* (n = 5) 1.00 (0.053) (n = 23)
EPP, end plate potential; MEPP, miniature endplate potential.
Values reported as mean (SEM).
*p,0.05; **p,0.001.
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Figure 1 Ultrastructural findings at the neuromuscular junction (NMJ). Control (A) and the patient (B–F). (A) Normal NMJ from a control
demonstrating normal nerve terminal size and highly complex postsynaptic membrane folding with well formed secondary synaptic clefts. The arrow
heads point to Schwann cell processes, which cap the nerve terminal (N), without extending into the synaptic cleft. The arrows point to the primary
synaptic cleft (top) and at a secondary synaptic cleft (bottom). The asterisk in A–C is placed over the Schwann cell. (B) Small nerve terminal partially
encased by a Schwann cell process, which intrudes into the synaptic space. (C) Small nerve terminal retracted from the synaptic space and completely
engulfed by the Schwann cell. Note also pronounced simplification of the postsynaptic membrane (arrow). (D) Bifurcated nerve terminal with one nerve
ending completely engulfed (top arrowhead) and the other ending partially encased (bottom arrowhead) by the Schwann cell. Note also pronounced
widening of the primary synaptic cleft and reduction of the density of synaptic vesicles in the nerve terminal. (E) Nerve terminal divided in three small
endings, which are encased by the Schwann cell and retracted from the postsynaptic membrane. (F) Pronounced reduction of the area of apposition
between the nerve terminal and the postsynaptic membrane, widening of primary synaptic cleft and invasion of the synaptic space by Schwann cell
processes (horizontal arrowheads). The vertical arrowheads point to two active zones, which in contrast to the control, are not apposing postsynaptic
secondary clefts. (G) and (H) Quantification of the area of apposition between the nerve and muscle. (G) Bar graph representing the average length of
apposition between nerve and muscle in 11 controls and 11 patient endplates. (H) Percentages of direct nerve–muscle apposition relative to the total
length of the synaptic cleft in 24 controls and 11 patient endplates (mean (SEM)). Calibration marks (A–F) represent 1 mm.
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DISCUSSION
Since each of the non-affected parents and the brother of the
patient carry only one of the mutations, the pattern of
inheritance of CMS associated with LAMB2 mutations is
autosomal recessive, as is the case with the majority of other
forms of CMS.1 2
While humans with pathogenic LAMB2 mutations have been
found to show the classical renal and ocular dysfunction of
Pierson syndrome, a missing piece of the puzzle has been the
absence of a clear demonstration in humans of the NMJ
involvement predicted by the animal model. This is likely due to
the short life span of patients with truncating LAMB2
mutations, as renal failure usually causes death within the first
year of life. Interestingly, longer survival rates in patients with
Pierson syndrome have recently been described; however, in the
majority of these cases, missense mutations were involved.18 19
Since missense mutations would predict some level of expres-
sion of synaptic laminins, it is possible that a minimal level of
expression of laminin may be sufficient to rescue the
neuromuscular phenotype.
The exceptional feature of our patient is that she has had an
unusually long life as a result of a successful renal replacement
therapy using a highly compatible kidney donated by her father
(she is still alive and well at the age of 20 years). This has
allowed the clinical manifestations of the failure of neuromus-
cular transmission to emerge.
In terms of the pathogenesis of this CMS, the structural
changes and the functional abnormalities of the NMJ encoun-
tered in our patient are strikingly similar to those reported in
Lamb22/2 mice. Thus, the extensive analysis performed in
Lamb22/2 and the conclusions drawn from this animal model
provide an invaluable key to understanding the pathogenesis of
the human neuromuscular disease reported here. First, as in
Lamb22/2 mice, our patient showed immature hypoplastic nerve
terminals, which in the animal model have been attributed to
the fact that laminin b2 acts as a potent ‘‘stop signal’’ for motor
Table 2 Morphometric data
Patient Control
EI* 5.68 (0.66)** (n = 24) 11.71 (2.36) (n = 12)
Secondary clefts per primary
cleft length
1.82 (0.19) (n = 24) 1.79 (0.14) (n = 12)
Nerve terminal area (mm2) 3.73 (0.53)*** (n = 24) 7.34 (0.93) (n = 12)
Number of synaptic vesicles/mm2 9.48 (1.14)** (n = 23) 16.77 (2.77) (n = 12)
Cleft width (mm) 0.16 (0.030)** (n = 11) 0.074 (0.0036) (n = 12)
*EI, endplate index (postsynaptic membrane length/presynaptic membrane length).
Values reported as mean (SEM).
**p,0.05; ***p,0.001.
Figure 2 Mutational analysis findings.
(A) Schematic view of the 32 coding
regions of human LAMB2 showing the
positions of the identified mutations in
exons 11 and 29. White regions
correspond to untranslated portions of the
gene. The 100 bp marker corresponds to
exons and introns. (B) Pedigree of the
family and the electropherograms
displaying the heterozygous frameshifting
1478delG and 4804delC mutations in the
patient, the heterozygous 1478delG
mutations and a normal sequence or wild
type (WT) in the non-affected mother, and
the heterozygous 4804delC mutation and
a WT sequence in the non-affected father
and brother. The arrows point to the
nucleotide deletions.
Figure 3 Western blot analysis. Results of a Western blot using a
rabbit polyclonal antibody directed against an epitope corresponding to
amino acids 1549–1798 of human laminin b2 (Santa Cruz Biotechnology,
Santa Cruz, California, USA) and frozen tissue from renal and muscle
biopsies of the patient. There is no laminin b2 expression in muscle and
renal tissues from the patient.
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neurite growth and promotes presynaptic differentiation in
vitro.15 20 21 It follows that in the absence of laminin b2, nerve
terminals fail to mature, remain hypoplastic and become
encased by cytoplasmic processes of the Schwann cell. The
abnormalities of the active zones that we encountered in our
patient have also been seen in the animal model22 and have been
attributed in part to a lack of interaction between the b2-chain
containing laminin 9 (a4/b2/c1) with the pore-forming (Cav)
subunit of the voltage gated calcium channel.23 24 This decrease
of active release sites, along with the reduction of nerve terminal
size and the dramatic decline of the area of apposition between
the nerve terminal and the postsynaptic membrane, accounts
for the distinctive depression of the EPP quantal content and
MEPP frequencies that characterise both the human disease and
the animal model.21 Second, the invasion of the synaptic space
by Schwann cell extensions found in our patient and in Lamb22/2
mice has been interpreted in the animal model as resulting
from the loss of the inhibitory effect that the b2 chain
containing laminin-11 exerts on Schwann cell propagation.20
Third, in our case, as in Lamb22/2, there was a simplification
of the postsynaptic folding pattern. This simplification of
postsynaptic folds may result from the lack of an interaction
between b2 chain containing laminins and cell surface
receptors for laminins such as integrins and dystroglycan
that participate in the development and maintenance of the
synaptic scaffold.11 13
Using tissue specific laminin b2 transgenes, it was recently
demonstrated that salvaging the glomerular defects with a
podocyte specific b2 transgene (NEPH- b2) does not signifi-
cantly improve the phenotype of the Lamb22/2 mutant, while
rescuing the structure of the NMJ with a muscle specific b2
transgene (MCK-B2) extends life by 50%.25 Clearly in the animal
model, defects of the NMJ are more devastating than kidney
abnormalities.
Since we see no obvious central nervous system defects in
humans, and since the ocular abnormalities are not lethal, the
NMJ disease may become the most serious complication in
patients with biallelic truncation mutations in LAMB2 and long
survival due to successful renal replacement therapy. From a
therapeutic perspective, drugs that increase the release of
neurotransmitter from the nerve terminal, such as 3,4-diamino-
pyridine, may be beneficial, but should be given with caution to
patients who, like ours, have profound distortion of the
function and architecture of the NMJ.
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